Page last updated: 2024-11-02

palmidrol and Pain

palmidrol has been researched along with Pain in 42 studies

palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.

Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.

Research Excerpts

ExcerptRelevanceReference
", PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA."7.85A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. ( Britti, D; Crupi, R; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Gugliandolo, E; Impellizzeri, D; Morittu, VM; Schievano, C, 2017)
" (1) The therapeutic effects of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder)."7.70The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. ( Hasnie, FS; Jaggar, SI; Rice, AS; Sellaturay, S, 1998)
" In inflamed bladders, URB937 had a U-shaped dose-response curve; following an initial cannabinoid receptor type 1-mediated reduction in pain responses and normalisation of bladder reflex activity, URB937 gradually increased both pain responses and bladder reflex activity through the transient receptor potential ion channel subfamily V member 1."5.56Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide/palmitoylethanolamine ratio in the inflamed bladder of rats. ( Charrua, A; Cruz, F; Marczylo, T; Matos, R; Nagy, I; Oliveira, R, 2020)
", PEA co-ultramicronized with the natural antioxidant quercetin (PEA-Q), administered orally in two different rat models of inflammatory and OA pain, namely carrageenan paw oedema and sodium monoiodoacetate (MIA)-induced OA."3.85A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models. ( Britti, D; Crupi, R; Cuzzocrea, S; Di Paola, R; Evangelista, M; Fusco, R; Gugliandolo, E; Impellizzeri, D; Morittu, VM; Schievano, C, 2017)
"The analgesic and anti-hyperalgesic effects of cannabinoid- and vanilloid-like compounds, plus the fatty acid amide hydrolase (FAAH) inhibitor Cyclohexylcarbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597), and acetaminophen, were evaluated in the phenyl-p-quinone (PPQ) pain model, using different routes of administration in combination with opioid and cannabinoid receptor antagonists."3.73Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. ( Cichewicz, DL; Haller, VL; Welch, SP, 2006)
"The potent analgesic effects of cannabis-like drugs and the presence of CB1-type cannabinoid receptors in pain-processing areas of the brain and spinal cord indicate that endogenous cannabinoids such as anandamide may contribute to the control of pain transmission within the central nervous system (CNS)."3.70Control of pain initiation by endogenous cannabinoids. ( Calignano, A; Giuffrida, A; La Rana, G; Piomelli, D, 1998)
" (1) The therapeutic effects of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder)."3.70The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. ( Hasnie, FS; Jaggar, SI; Rice, AS; Sellaturay, S, 1998)
"The aim of the study was to assess the safety, tolerability and efficacy of palmitoylethanolamide (PEA) when dosed at 300 mg and 600 mg per day on symptoms of knee osteoarthritis."2.90A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. ( Steels, E; Venkatesh, R; Vitetta, G; Vitetta, L, 2019)
" For treatment times up to 49 days, the current clinical data argue against serious adverse drug reactions (ADRs) at an incidence of 1/200 or greater."2.53Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy. ( Fowler, CJ; Gabrielsson, L; Mattsson, S, 2016)
" Clinical trials are now required, but are hindered by a paucity of cannabinoids of suitable bioavailability and therapeutic ratio."2.41Cannabinoids and pain. ( Rice, AS, 2001)
" In inflamed bladders, URB937 had a U-shaped dose-response curve; following an initial cannabinoid receptor type 1-mediated reduction in pain responses and normalisation of bladder reflex activity, URB937 gradually increased both pain responses and bladder reflex activity through the transient receptor potential ion channel subfamily V member 1."1.56Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide/palmitoylethanolamine ratio in the inflamed bladder of rats. ( Charrua, A; Cruz, F; Marczylo, T; Matos, R; Nagy, I; Oliveira, R, 2020)
"The prevalence of idiopathic vulvodynia and proctodynia is high."1.40Vulvodynia and proctodynia treated with topical baclofen 5 % and palmitoylethanolamide. ( Keppel Hesselink, JM; Kopsky, DJ; Sajben, NL, 2014)
" The lipidic nature and large particle size of PEA in the native state may limit its solubility and bioavailability when given orally, however."1.40Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. ( Bruschetta, G; Cordaro, M; Crupi, R; Cuzzocrea, S; Esposito, E; Impellizzeri, D; Siracusa, R, 2014)
"Effects of pre-treatment with a single dose, versus 4 day repeated dosing with the selective FAAH inhibitor, URB597 (i."1.38Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. ( Alexander, SP; Barrett, DA; Bennett, AJ; Burston, J; Chapman, V; Kendall, DA; Norris, LM; Okine, BN; Patel, A; Woodhams, S, 2012)

Research

Studies (42)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (4.76)18.2507
2000's9 (21.43)29.6817
2010's22 (52.38)24.3611
2020's9 (21.43)2.80

Authors

AuthorsStudies
Lang-Illievich, K1
Klivinyi, C1
Rumpold-Seitlinger, G1
Dorn, C1
Bornemann-Cimenti, H1
Toti, A1
Micheli, L1
Lucarini, E1
Ferrara, V1
Ciampi, C1
Margiotta, F1
Failli, P1
Gomiero, C1
Pallecchi, M1
Bartolucci, G1
Ghelardini, C1
Di Cesare Mannelli, L1
Huschtscha, Z1
Fyfe, JJ1
Feros, SA1
Betik, AC1
Shaw, CS1
Main, LC1
Abbott, G1
Tan, SY1
Refalo, MC1
Gerhardy, M1
Grunwald, E1
May, A1
Silver, J1
Smith, CM1
White, M1
Hamilton, DL1
Salaffi, F1
Farah, S1
Sarzi-Puttini, P1
Di Carlo, M1
Cuzzocrea, S8
Crupi, R4
Charrua, A1
Matos, R1
Oliveira, R1
Marczylo, T1
Nagy, I1
Cruz, F1
Petrosino, S3
Schiano Moriello, A1
Ardizzone, A1
Fusco, R3
Casili, G1
Lanza, M1
Impellizzeri, D4
Esposito, E4
Clayton, P1
Hill, M1
Bogoda, N1
Subah, S1
Venkatesh, R2
Britti, D1
Gugliandolo, E2
Schievano, C1
Morittu, VM1
Evangelista, M2
Di Paola, R2
Gorelik, A1
Gebai, A1
Illes, K1
Piomelli, D5
Nagar, B1
Aldossary, SA1
Alsalem, M1
Kalbouneh, H1
Haddad, M1
Azab, B1
Al-Shboul, O1
Mustafa, AG1
Obiedat, S1
El-Salem, K1
Steels, E2
Vitetta, G1
Vitetta, L1
Zhou, P1
Xiang, L1
Yang, Y1
Wu, Y1
Hu, T1
Liu, X1
Lin, F1
Xiu, Y1
Wu, K1
Lu, C1
Ren, J1
Qiu, Y1
Li, Y1
Davis, MP1
Behm, B1
Mehta, Z1
Fernandez, C1
Peritore, AF1
Cordaro, M2
Siracusa, R2
D'Amico, R1
Descalzi, F1
Ulivi, V1
Cancedda, R1
Piscitelli, F1
Luongo, L1
Guida, F1
Gatta, L1
Maione, S1
Di Marzo, V4
Keppel Hesselink, JM1
Kopsky, DJ1
Sajben, NL1
Mattace Raso, G1
Russo, R2
Calignano, A5
Meli, R2
Bruschetta, G1
Koltyn, KF1
Brellenthin, AG1
Cook, DB1
Sehgal, N1
Hillard, C1
Ahmad, A1
Marcolongo, G1
Allarà, M1
Verde, R1
Donvito, G1
Bettoni, I1
Comelli, F1
Colombo, A1
Costa, B1
Gabrielsson, L1
Mattsson, S1
Fowler, CJ1
Okine, BN2
Madasu, MK1
McGowan, F1
Prendergast, C1
Gaspar, JC1
Harhen, B1
Roche, M1
Finn, DP1
Loría, F1
Mestre, L1
Spagnolo, A1
Correa, F1
Hernangómez, M1
Guaza, C1
Docagne, F1
Karbarz, MJ1
Luo, L1
Chang, L1
Tham, CS1
Palmer, JA1
Wilson, SJ1
Wennerholm, ML1
Brown, SM1
Scott, BP1
Apodaca, RL1
Keith, JM1
Wu, J1
Breitenbucher, JG1
Chaplan, SR1
Webb, M1
Sasso, O1
Vitiello, S1
Raso, GM1
D'Agostino, G1
Iacono, A1
La Rana, G4
Vallée, M1
Piazza, PV1
Naderi, N1
Majidi, M1
Mousavi, Z1
Khoramian Tusi, S1
Mansouri, Z1
Khodagholi, F1
Truini, A1
Biasiotta, A1
Di Stefano, G1
La Cesa, S1
Leone, C1
Cartoni, C1
Federico, V1
Petrucci, MT1
Cruccu, G1
Norris, LM1
Woodhams, S1
Burston, J1
Patel, A1
Alexander, SP1
Barrett, DA1
Kendall, DA1
Bennett, AJ1
Chapman, V1
Re, G1
Barbero, R1
Miolo, A1
Breathnach, R1
Haller, VL1
Cichewicz, DL1
Welch, SP1
Wallace, VC1
Segerdahl, AR1
Lambert, DM1
Vandevoorde, S1
Blackbeard, J1
Pheby, T1
Hasnie, F1
Rice, AS3
Giuffrida, A1
Jaggar, SI1
Hasnie, FS1
Sellaturay, S1
Loubet-Lescoulié, P1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Palmitoylethanolamide on Reducing Opioid Consumption for Postoperative Pain and Inflammation Following Below Knee Fracture Fixation: A Pilot Study.[NCT05317676]Phase 20 participants (Actual)Interventional2023-05-31Withdrawn (stopped due to Sponsor suspending temporarily.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

9 reviews available for palmidrol and Pain

ArticleYear
Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries-A Systematic Review.
    International journal of molecular sciences, 2020, Dec-15, Volume: 21, Issue:24

    Topics: Alzheimer Disease; Amides; Amyotrophic Lateral Sclerosis; Animals; Autism Spectrum Disorder; Endocan

2020
Palmitoylethanolamide: A Natural Compound for Health Management.
    International journal of molecular sciences, 2021, May-18, Volume: 22, Issue:10

    Topics: Amides; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Dietary Suppleme

2021
The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review.
    The American journal of hospice & palliative care, 2019, Volume: 36, Issue:12

    Topics: Amides; Animals; Ethanolamines; Humans; Mental Disorders; Neurodegenerative Diseases; Pain; Palmitic

2019
Palmitoylethanolamide in CNS health and disease.
    Pharmacological research, 2014, Volume: 86

    Topics: Amides; Animals; Anti-Inflammatory Agents; Central Nervous System; Ethanolamines; Humans; Inflammati

2014
Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy.
    British journal of clinical pharmacology, 2016, Volume: 82, Issue:4

    Topics: Amides; Analgesics; Ethanolamines; Humans; Pain; Palmitic Acids

2016
Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma.
    Mini reviews in medicinal chemistry, 2013, Volume: 13, Issue:2

    Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Endocannabinoids; Ethanolamine

2013
Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals.
    Veterinary journal (London, England : 1997), 2007, Volume: 173, Issue:1

    Topics: Amides; Analgesics; Animals; Cannabinoids; Endocannabinoids; Ethanolamines; Inflammation; Pain; Palm

2007
A role for the endogenous cannabinoid system in the peripheral control of pain initiation.
    Progress in brain research, 2000, Volume: 129

    Topics: Amides; Analgesics; Animals; Arachidonic Acids; Brain; Cannabinoids; Drug Interactions; Endocannabin

2000
Cannabinoids and pain.
    Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:3

    Topics: Amides; Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Benzoxazines; Brain; Camphanes; Can

2001

Trials

5 trials available for palmidrol and Pain

ArticleYear
The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial.
    Nutrients, 2022, Oct-01, Volume: 14, Issue:19

    Topics: Amides; Analgesics; Anti-Inflammatory Agents; Cross-Over Studies; Double-Blind Method; Ethanolamines

2022
A randomised controlled trial assessing the potential of palmitoylethanolamide (PEA) to act as an adjuvant to resistance training in healthy adults: a study protocol.
    Trials, 2023, Mar-31, Volume: 24, Issue:1

    Topics: Adolescent; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Australia; Dietary Supplemen

2023
Palmitoylethanolamide and acetyl-L-carnitine act synergistically with duloxetine and pregabalin in fibromyalgia: results of a randomised controlled study.
    Clinical and experimental rheumatology, 2023, Volume: 41, Issue:6

    Topics: Acetylcarnitine; Analgesics; Duloxetine Hydrochloride; Fibromyalgia; Humans; Pain; Pregabalin; Treat

2023
A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis.
    Inflammopharmacology, 2019, Volume: 27, Issue:3

    Topics: Adult; Aged; Amides; Anti-Inflammatory Agents, Non-Steroidal; Depressive Disorder, Major; Double-Bli

2019
Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy.
    CNS & neurological disorders drug targets, 2011, Volume: 10, Issue:8

    Topics: Aged; Aged, 80 and over; Amides; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; End

2011

Other Studies

28 other studies available for palmidrol and Pain

ArticleYear
Ultramicronized
    Biomolecules, 2023, 01-25, Volume: 13, Issue:2

    Topics: Analgesics, Opioid; Astrocytes; Drug Tolerance; Humans; Mast Cells; Morphine; Pain

2023
To Go Where Nature Leads: Focus on Palmitoylethanolamide and Related ALIAmides as Innovative Approach to Neuroinflammatory and Pain-Related Disease States in Honor of Doctor Francesco Della Valle.
    Biomolecules, 2023, Oct-26, Volume: 13, Issue:11

    Topics: Amides; Ethanolamines; Humans; Pain; Palmitic Acids

2023
Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide/palmitoylethanolamine ratio in the inflamed bladder of rats.
    Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:2

    Topics: Amides; Amidohydrolases; Animals; Arachidonic Acids; Cannabinoids; Cystitis; Endocannabinoids; Ethan

2020
Effect of Ultra-Micronized-Palmitoylethanolamide and Acetyl-l-Carnitine on Experimental Model of Inflammatory Pain.
    International journal of molecular sciences, 2021, Feb-17, Volume: 22, Issue:4

    Topics: Acetylcarnitine; Amides; Animals; Carrageenan; Cell Count; Cyclooxygenase 2; Disease Models, Animal;

2021
A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models.
    BMC veterinary research, 2017, Aug-02, Volume: 13, Issue:1

    Topics: Administration, Oral; Amides; Animals; Anti-Inflammatory Agents; Carrageenan; Drug Combinations; Ede

2017
Molecular mechanism of activation of the immunoregulatory amidase NAAA.
    Proceedings of the National Academy of Sciences of the United States of America, 2018, 10-23, Volume: 115, Issue:43

    Topics: Amides; Amidohydrolases; Analgesics; Animals; Catalytic Domain; Cell Line; Drug Discovery; Enzyme In

2018
The role of transient receptor potential vanilloid receptor 1 and peroxisome proliferator-activated receptors-α in mediating the antinociceptive effects of palmitoylethanolamine in rats.
    Neuroreport, 2019, 01-02, Volume: 30, Issue:1

    Topics: Amides; Analgesics; Animals; Disease Models, Animal; Ethanolamines; Ganglia, Spinal; Male; Nocicepti

2019
N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritis.
    Pharmacological research, 2019, Volume: 145

    Topics: Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents; Cartilage; Cells, Cultured; Chondrocytes

2019
The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:10

    Topics: Amides; Analgesics; Animals; Anti-Inflammatory Agents; Apoptosis; Cytokines; Diabetic Neuropathies;

2019
Platelet-rich plasma exerts antinociceptive activity by a peripheral endocannabinoid-related mechanism.
    Tissue engineering. Part A, 2013, Volume: 19, Issue:19-20

    Topics: Amides; Analgesics; Animals; Arachidonic Acids; Blotting, Western; Cell Line, Tumor; Endocannabinoid

2013
Vulvodynia and proctodynia treated with topical baclofen 5 % and palmitoylethanolamide.
    Archives of gynecology and obstetrics, 2014, Volume: 290, Issue:2

    Topics: Administration, Topical; Adult; Amides; Anti-Inflammatory Agents, Non-Steroidal; Anus Diseases; Bacl

2014
Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain.
    Journal of neuroinflammation, 2014, Aug-28, Volume: 11

    Topics: Administration, Oral; Amides; Analgesics; Animals; Carrageenan; Chemistry, Pharmaceutical; Chromatog

2014
Mechanisms of exercise-induced hypoalgesia.
    The journal of pain, 2014, Volume: 15, Issue:12

    Topics: Adolescent; Adult; Amides; Arachidonic Acids; Cross-Over Studies; Double-Blind Method; Endocannabino

2014
Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain.
    Pharmacological research, 2015, Volume: 91

    Topics: Amides; Amidohydrolases; Analgesics; Animals; Anthraquinones; Anti-Inflammatory Agents; Carrageenan;

2015
Palmitoylethanolamide relieves pain and preserves pancreatic islet cells in a murine model of diabetes.
    CNS & neurological disorders drug targets, 2015, Volume: 14, Issue:4

    Topics: Amides; Analgesics; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Ethanolamines;

2015
N-palmitoylethanolamide in the anterior cingulate cortex attenuates inflammatory pain behaviour indirectly via a CB1 receptor-mediated mechanism.
    Pain, 2016, Volume: 157, Issue:12

    Topics: Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cannabinoid Receptor Antagonists; Cohort S

2016
Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide.
    The European journal of neuroscience, 2008, Volume: 28, Issue:4

    Topics: Amides; Animals; Anti-Inflammatory Agents; Antiviral Agents; Cannabinoid Receptor Modulators; Cytoki

2008
Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
    Anesthesia and analgesia, 2009, Volume: 108, Issue:1

    Topics: Amides; Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Brain; Carrageenan; Disease Models,

2009
Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain.
    Pain, 2012, Volume: 153, Issue:1

    Topics: Amides; Analgesics; Animals; Endocannabinoids; Ethanolamines; Hyperalgesia; Male; Mice; Pain; Pain M

2012
A thickening network of lipids.
    Pain, 2012, Volume: 153, Issue:1

    Topics: Amides; Analgesics; Animals; Endocannabinoids; Ethanolamines; Male; Pain; Palmitic Acids; Pregnanolo

2012
The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-β expression in rats.
    Neurochemical research, 2012, Volume: 37, Issue:4

    Topics: Amides; Animals; Drug Interactions; Endocannabinoids; Ethanolamines; Injections, Spinal; Interleukin

2012
Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system.
    British journal of pharmacology, 2012, Volume: 167, Issue:3

    Topics: Amides; Amidohydrolases; Animals; Arachidonic Acids; Behavior, Animal; Benzamides; Carbamates; Disea

2012
The psychedelic haze of inflammation.
    Veterinary journal (London, England : 1997), 2007, Volume: 173, Issue:1

    Topics: Amides; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cannabinoids; Endocann

2007
Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
    European journal of pharmacology, 2006, Sep-28, Volume: 546, Issue:1-3

    Topics: Acetaminophen; Amides; Analgesics; Animals; Arachidonic Acids; Benzamides; Benzoquinones; Camphanes;

2006
The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy.
    British journal of pharmacology, 2007, Volume: 151, Issue:7

    Topics: Amides; Amines; Animals; Behavior, Animal; Camphanes; Cyclohexanecarboxylic Acids; Dose-Response Rel

2007
Control of pain initiation by endogenous cannabinoids.
    Nature, 1998, Jul-16, Volume: 394, Issue:6690

    Topics: Amides; Analgesics; Animals; Arachidonic Acids; Cannabinoids; Drug Synergism; Endocannabinoids; Etha

1998
The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain.
    Pain, 1998, Volume: 76, Issue:1-2

    Topics: Amides; Analgesics; Animals; Arachidonic Acids; Cannabinoids; Capillary Permeability; Cystitis; Elec

1998
Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide.
    European journal of pharmacology, 2001, May-11, Volume: 419, Issue:2-3

    Topics: Amides; Analgesics; Analysis of Variance; Animals; Arachidonic Acids; Calcium Channel Blockers; Camp

2001